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ABSTRACT: Microtubule affinity-regulating kinase 4 (MARK4),
a member of the serine/threonine kinase family, is an emerging
therapeutic target in anticancer drug discovery paradigm due to its
involvement in regulation of microtubule dynamics, cell cycle
regulation, and cancer progression. Therefore, to identify the novel
chemical architecture for the design and development of novel
MARK4 inhibitors with concomitant radical scavenging property, a
series of small-molecule arylaldoxime/5-nitroimidazole conjugates
were designed and synthesized via multistep chemical reactions
following the pharmacophoric hybridization approach. Compound
4h was identified as a promising MARK4 inhibitor with high
selectivity toward MARK4 inhibition as compared to the panel of
screened 30 kinases pertaining to the serine/threonine family, which was validated by molecular docking and fluorescence binding
studies. The comprehensive cell-based examination divulged the promising apoptotic, antiproliferative, and antioxidant potential for
the chemotype 4h. The compound 4h was endowed with the Ka value of 3.6 × 10
3 M−1 for human serum albumin, which reflects its
remarkable transportation and delivery properties to the target site via blood. The present study impedes that in the future, such
compounds may stand as optimized pharmacological lead candidates in drug discovery for targeting cancer via MARK4 inhibition
with a remarkable anticancer profile.
■ INTRODUCTION
Design and development of anticancer agents has been a
challenging task for the scientific community and a wide range
of active targets are being exploited to combat this devastating
disease.1−3 Kinases are considered as one of the most
intensively pursued targets in current pharmacological
research, particularly for cancer, due to their critical roles in
cellular signaling.4,5 Kinases catalyze the transfer of the γ-
phosphate group of adenosine 5′-triphosphate (ATP) onto a
substrate, mediate most signal transductions,6 and regulate
various cellular activities, including proliferation, survival,
apoptosis, metabolism, transcription, differentiation, and a
wide array of other cellular processes.7,8 Microtubule affinity-
regulatory kinase 4 (MARK4), a member of the Ser/Thr
kinase family, has emerged as an important therapeutic target
for anticancer drug development recently.9,10 MARK4 is coded
by genes located on the chromosome number 19 in the human
genome11 and it abets the breast cancer cell proliferation as
well as migration through the inhibition of Hippo signaling.12
MARK4 enhances adipogenesis and triggers cellular apoptosis
by activating JNK1 and by inhibiting the p38MAPK path-
ways.13 It gets overexpressed in cancerous cells including
hepatocarcinoma and leukemia and plays a significant role in
the promotion of breast and prostate cancers.14 Therefore,
MARK4 has emerged as an important therapeutic target in the
anticancer drug discovery paradigm.
MARK4 carries out the phosphorylation of the microtubule-
associated proteins (MAPs) by using ATP at the binding
domain Lys-Xaa-Gly-Ser (KXGS) motif.11 The process of
phosphorylation maintains the cell polarity, microtubule
stability, protein stability, intracellular signaling, cell cycle
control, cell division specifically in the G1/S checkpoint, and
many other complex cellular processes due to the detachment
of MAPs from microtubule assembly.15,16 Phosphorylation of
MARK4 at Thr214 residue activates the microtubule
dynamics; however, the attachment of the phosphate group
at Ser218 residue inhibits its function. Asp181 is the active site
of MARK4, which in turn gets activated by phosphorylation of
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Thr214 residue.14 Mostly, the kinase-inhibiting agents are
reversible, and ATP competitive inhibitors bind in the ATP-
binding pocket of the kinase protein. Vemurafenib (1), S49076
(2), and nilotinib (3) (Figure 1) are some of the FDA-
approved kinase inhibitors, which function by binding at the
ATP binding domain of kinases.4,17 The imidazole motif is the
important fragment of nilotinib and vemurafenib, which aid in
promoting the function of these approved molecules with the
binding pocket of their respective kinases.4,18 Over the years,
electron-deficient nitroaromatic compounds have been inves-
tigated for use in cancer treatment and, likely, the nitro-
imidazole derivatives have been reported as potent mitogen-
activated protein (MAP) kinase inhibitors.19,20 A perusal of
literature reveals that oximes act as a core structural motif of
myriad chemotypes endowed with anticancer activities
including kinase inhibition.21−23 Designing hybrid molecules
in which two or more pharmacophores are covalently linked is
a rationally attractive approach toward the development of
effective therapeutic molecules. The pharmacophoric hybrid-
ization approach results in the development of promising
chemotherapeutic agents having different modes of action and
reduced side effects.24
Further, the small molecules play a pivotal role in the
inhibition of various kinases pertaining to the human kinome
and are being utilized extensively in the drug development.8,25
Considering the important pharmacological properties, viz.,
ease in cellular diffusion, membrane permeability, transport,
bioavailability, binding affinity, and potency associated with
small ring heterocyclic motifs,26−28 the molecular hybridization
approach was employed to graft a 5-nitroimidazole scaffold
with a pharmacologically important oxime core to construct
novel hybrid miniature chemotypes as a new class of potential
MARK4 inhibitors. Also, as the MARK4 expression plays a
crucial role in the induction of oxidative stress in adipocytes
and, therefore, the inhibition of MARK4 may result in the
reduction of reactive oxygen species (ROS) generation, which
therefore relieves the oxidative stress in cells.29−31 Therefore,
considering the above-mentioned facts and our earlier reports
on microtubule affinity-regulating kinase 4,32−34 we herein
report the design and synthesis of novel arylaldoxime/5-
nitroimidazole conjugates as potent MARK4 inhibitors and
antioxidant agents with remarkable anticancer activity.
■ RESULTS
Design. Human kinases possess the β sheet protein folding
pattern dominating on N-terminal side and α helix pattern in
the C-terminal lobe, which are connected by a hinge region
sequence. The ATP carries out the phosphorylation by binding
Figure 1. Structural resemblance of the identified small-molecule MARK4 inhibitor 4h with some reported kinase inhibitors 1−3.
Scheme 1. Synthetic Route Adopted for the Preparation of Arylaldoxime/5-Nitroimidazole Hybrids 4a−4ha
aReagents and conditions: (a) NH4OH·HCl, 3 N NaOH, EtOH, reflux, 14−20 h; (b) NCS, DMF, 60 °C, 8−12 h; (c) 2-methyl-4(5)-
nitroimidazole, TBAB, K2CO3, ACN, reflux, 3−4 h.
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in the cleft formed between the N- and C-terminal lobes of the
kinase protein.4,35 The X-ray crystallography established that
the MARK4 protein comprises of a catalytic domain, short
linker sequence, ubiquitin-associated (UBA) domain bound to
the N-terminal lobe of the catalytic domain, spacer domain,
and globular kinase-associated domain (KA). The catalytic
domain is the site of interest for targeting the phosphorylation
process.36 The smaller ATP competitors have the major access
to interact with the active residues of the kinase protein and
hence show maximum inhibition potential.8,37
Oxime-derived compounds have been established to inhibit
the kinase function by interacting at the ATP binding site and
therefore prevent the phosphorylation process, which in turn
disrupts the microtubule assembly.38,39 The nitroimidazole
ring is the fragment of diverse promising kinase inhib-
itors20,40,41 and interacts with the various cleft residues via π
electron cloud and the oxygen atoms, hence showing
appreciable binding affinity with MARK4 as per in silico
screening (Table S1). The docking simulation technique was
employed for binding affinity assessment of our designed
compounds with MARK4 and then the attempt was made for
their synthesis. In silico screening of our initial compound 4a of
Scheme 1 showed that one of the oxygen atoms of the nitro
group interacts via hydrogen bonding with Asp196 and the
other oxygen atom interacts by van der Waals interactions with
Lys85 besides making a hydrogen bond with Asp196 residue of
the catalytic domain of MARK4 protein. The five-membered
heterocyclic aromatic imidazole ring makes the π−sigma
interactions with Val70. The phenyl substituent interacts via
π−alkyl interactions with Ala195 and Ala83 and via the π−
sigma interaction with Val70. The nitrogen atom of oxime core
shows polar interactions with Asp196, whereas its oxygen-
bonded hydrogen atom forms the hydrogen bond with the
Asp196 residue (Figure S1). Convinced by in silico analysis of
the designed compounds, the remarkable affinity of small
molecules toward kinase inhibition, and the potency of the
chosen scaffolds, we intended to synthesize novel arylaldoxime
hybrids of 5-nitroimidazole heterocycle following the molec-
ular hybridization approach to formulate and identify the small
MARK4 inhibitors with the optimization of enhanced
bioeffects.
Synthesis. A series of arylaldoxime/5-nitroimidazole
hybrid molecules (Scheme 1) were synthesized starting from
the synthesis of different arylaldoximes (2a−2h), which were
further converted into their corresponding carboximidoyl
chlorides (3a−3h) via N-chlorosuccinimide (NCS)-mediated
chlorination. Initially, the carboximidoyl chlorides (3a−3h)
were reacted with 2-methyl-4(5)-nitroimidazole in the
presence of K2CO3 using DMF as the solvent under reflux,
but the reaction time was exceeding 72 h with the formation of
side products as well and the overall yield was very low (20−
25%). To overcome these hurdles, tetra-n-butylammonium
bromide (TBAB) was employed as a phase transfer catalyst.
Mechanistically, the solid−liquid phase transfer catalyst TBAB
replaces the potassium ion from imidazolium-potassium salt to
form the quaternary ammonium salt of 2-methyl-4(5)-
nitroimidazole, which is much more dissociated in the organic
phase (ACN) than its potassium salt and hence more reactive.
The quaternary salt reacts with the carboximidoyl chlorides
(electrophile in the organic phase) to form the target
molecules (4a−4h).
The TBAB increases the nucleophilicity and transport of the
imidazolium ion into the organic phase and therefore leads to
the increase in yield and reduced reaction time.42 Therefore,
the attempt of employing the TBAB as a phase transfer catalyst
(solid−liquid phase-transfer system) increased the credible
yield of desired products, reduced the reaction completion
time, predominantly prevented the occurrence of other side
reactions, and resulted in the preferable nucleophilic
substitution at the desired position of the nitroimidazole
ring.43,44 Structures of the synthesized target compounds were
elucidated by 1H NMR, 13C NMR, ESI-MS spectral data, and
X-ray, and their purity was confirmed by elemental analysis.
The compounds were of ≥95% purity grade.
Single-Crystal Data. Single-crystal structures of com-
pounds 4c and 4e were isolated and were suitable to measure
by the X-ray method. The compound 4c crystallizes in a
monoclinic crystal system and compound 4e in an
orthorhombic crystal system (Table 1). The compound 4e,
which crystallize in the orthorhombic crystal system, contains
two molecules in the asymmetric unit, which correspond with
two atropoisomers. These atropoisomers are present in all the
structures. Friedel pairs were determined and their number was
25,280. ORTEP diagrams for compounds 4c and 4e are shown
in Figure 2. The molecular structures present similar bond
lengths and angles with that of the other compounds having
similar functional groups (Table S4). Intermolecular hydrogen
bonds and van der Waals forces predominate in their crystal
packings (Table S5), and they can be the key of their
interaction with the biomolecules and their bioactivity.
Molecular Docking. Binding affinities and the mode of
binding of all the synthesized molecules with MARK4 were
evaluated by the help of molecular docking. Autodock Vina
Table 1. Crystal Data and Structure Refinement for
Compounds 4c and 4e
compound 4c 4e
formula C12 H12 N4 O3 C13 H14 N4 O3
formula weight 260.26 274.28
T (K) 100(2) 100(2)
wavelength (Å) 0.71073 0.71073
crystal system monoclinic orthorhombic
space group P21/n P21212
a (Å) 6.2087(5) 14.154(5)
b (Å) 15.2664(10) 14.763(5)
c (Å) 13.4466(9) 13.021(4)
α (°) 90 90
β (°) 100.463(3) 90
γ (°) 90 90





μ (mm−1) 0.103 0.098
θ (°) 2.67 to 28.32 2.53 to 26.38
Rint 0.0913 0.0646
crystal size (mm3) 0.08 × 0.10 × 0.20 0.07 × 0.07 × 0.24





largest difference peak and
hole (e Å−3)
0.347 and −0.299 0.364 and −0.398
aR1 = Σ||Fo| − |Fc||/Σ|Fo|. bwR2 = {Σ|[w(||Fo|2 − |Fc|2|)2]|/
Σ[w(Fo2)2]}1/2.
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combined with PyRx software was used to check out the
interactions offered by the active site residues of MARK4 with
each synthesized molecule (ligand).45,46 Our first objective was
to validate the binding of the initial designed compound 4a in
the active site of MARK4. Compound 4a showed an efficient
binding with the active site of MARK4 (Figure S1). After the
validation of binding affinity of the designed initial compound
4a, we have synthesized further derivatives incorporating
various aryl substituents. The binding energy and list of
MARK4 residues interacting to the ligands are given in Table
S1, Figure 3, and Figures S1−S3. All synthesized hybrid
molecules showed an appreciable binding energy ranging
between −6.8 and −7.6 kcal/mol (Table S1). Docking results
showed that each MARK4−ligand (4a−4h) complex is
stabilized by a significant number of noncovalent interactions
(hydrogen bond and van der Waals) offered by the residues
lying in the active site region of MARK4 (Figure 3 and Figures
S1−S3). These results supported our motivation to synthesize
such a class of MARK4 inhibitors that bind efficiently to the
active site residues and consequently diminish the enzymatic
activity. The consistency of docking protocol was evaluated by
redocking the known inhibitor of MARK4 (pyrazolopyrimidine
inhibitor 5RC) into the active site of the MARK4.
MARK4 Inhibition and Structure−Activity Relation-
ship (SAR). After the in silico validation of binding affinities of
synthesized molecules, we performed MARK4 enzyme
inhibition assay using ATPase hydrolysis. To peruse this
study, we have expressed and purified the recombinant
MARK4 protein, as described earlier.29 All the synthesized
molecules were evaluated against MARK4 at a single dose of
20 μM and it was found that only one compound (4h) showed
significant inhibition. On the basis of initial screening,
compound 4h was being considered for further MARK4
inhibition assay purposes with its increasing concentrations
(0−20 μM) (Figure 4). Enzyme inhibition studies revealed
that compound 4h inhibited the activity of MARK4 with IC50
values of 1.74 μM. The results of docking and enzyme assay
showed that compound 4h binds to the active site of MARK4
and significantly inhibits its activity.
Since the variation was done on the either side of the oxime
core for the determination of the impact of the varied
electronic arrangement on the activity of the target molecules.
All the evaluated compounds of Scheme 1 share two similar
structural features: (i) central oxime core and (ii) hydrophobic
fragment (ring A, Figure 5). In Scheme 1, the −NOH group
was coupled with 2-methyl-4(5)-nitroimidazole scaffold (ring
B) (Figure 5). The initial compound (4a) bearing an
unsubstituted phenyl ring was observed to be less potent
(Table 2) when evaluated for MARK4 inhibitory activity.
However, the introduction of electron-releasing groups
(ERGs), viz., OCH3 (4b), CH3 (4c), C2H5 (4d), OC2H5
(4e), and Cl (4f), at the C-4 position in ring A as R1
substituents still leads to the minimal MARK4 inhibition.
The replacement of these ERGs with the strongly electron-
withdrawing NO2 group (4g) at the same position resulted in
the slight enhancement in the potency. Surprisingly, multifold
MARK4 inhibition was observed when the CF3 group was
incorporated as the R2 substituent in ring A, keeping the C-4
position unsubstituted (4h, IC50 = 1.47 μM, Table 2).
The inhibitory activity shown by the electron-withdrawing
groups was more effective as compared to the electron-
releasing groups in the entire series. Therefore, in terms of
structure−activity relationship (SAR), it can be concluded that
the MARK4 inhibition of studied hybrids was substituent-
dependent. The compounds having the −CF3 group were the
most potent among all the chemotypes, which supported the
earlier reports that the compounds bearing the trifluoromethyl
group occupy prime importance in medicinal chemistry due to
their significant drug-like properties, viz., remarkable lip-
ophilicity, absorption, and metabolic stability.47,48 Moreover,
the presence of −CF3 group may have drifted the activity of
the compound 4h due to its inevitable physiological
significance mostly in terms of conferring the excellent
lipophilicity and absorption to the molecules across the
cellular plasma membrane.
Kinase Selectivity of Compound 4h. Kinase inhibitors
generally showed off-target activities with same/different
kinase families. Therefore, to check out the selectivity of
compound 4h, we evaluate it against a panel of 30 kinases of
the same family (CAMK family). The results of selectivity
showed that compound 4h inhibited MARK4 more strongly as
compared to other kinases of the same family (Figure 6). The
inhibition results indicated that at the tested concentration, the
compound 4h moderately inhibits MARK1, CAMKIV,
MAPKAPK2, and DAPK1 (Table S2). It may be due to the
similar/conserved binding pockets of these kinases. Impor-
tantly, kinase selectivity results suggested that compound 4h
possesses high selectivity toward MARK4 inhibition.
Binding Affinity toward MARK4 and HSA. To estimate
the actual binding affinity of compound 4h toward MARK4
and human serum albumin (HSA), fluorescence binding assay
Figure 2. ORTEPs diagrams for the arylaldoxime-nitroimidazole
hybrids 4c and 4e. All the nonhydrogen atoms are presented by their
50% probability ellipsoids. Drawing was done with the SHELXL
package.
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was performed. In each case, the protein sample was excited at
280 nm and the emission spectra were recorded in the range of
300−400 nm with increasing concentrations of the selected
compound. A decrease in the fluorescence intensity of
MARK4/HSA with increasing concentrations of compound
4h was analyzed using a modified Stern−Volmer equation to
estimate the binding constant Ka (Figure 7). For MARK4, the
value of Ka for the compound 4h was found to be 8.7 × 10
6
M−1. However, the binding constant for HSA was observed to
be 3.6 × 103 M−1 for this compound. The results clearly
indicated that compound 4h binds strongly with MARK4.
However, modest binding affinity was observed for HSA,
indicating a desired transport affinity as drugs/drug-like
Figure 3. Compound 4h binds to the active site of MARK4. (A) 3D presentation of MARK4 docked ligand complex of compound 4h (purple) to
the active site residues of MARK4. (B) Focused view of MARK4 binding pocket with compound 4h shows the hydrogen bond donor−acceptor
residues of protein. (C) 2D representation of residues involved in different interactions like van der Waals interactions, hydrogen bonding, charge,
or polar interactions (each type of interaction is represented by respective color; see inset).
Figure 4. Compound 4h inhibited the kinase activity of MARK4. (A)
Hydrolysis of Pi from ATP. The position of Pi and ATP spots are
indicated. Lane 1, negative control (no protein); lane 2, 100 nM
MARK4 (positive control); lanes labeled as 0.5, 1, 2, 5, 10, and 20,
concentration of the compound. (B) ATPase inhibition (% hydrolysis
of Pi) with increasing concentrations of compound 4h is shown as a
function of concentration calculated by comparing with the positive
control.
Figure 5. General structure of the designed chemotypes depicting the
strategic variation of nitroaromatic scaffold (ring B) with a central
oxime core bearing the hydrophobic fragment (ring A).
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molecules. HSA is the main carrier component of the
bloodstream responsible for the transport of different
molecules and the molecules possessing HSA binding affinities
will be easy to transport.32 Thus, the moderate HSA binding
affinity of the compound 4h supported its transportable
properties.
Inhibition of Cancer Cell Proliferation. To evaluate the
antiproliferation potential of compound 4h on human cancer
cell lines (MCF-7 and HepG2), MTT-based cell viability assay
was carried out and consequential IC50 values were calculated.
We observed that compound 4h was toxic to MCF-7 and
HepG2 cancerous cells. The molecule inhibited the growth of
these cells in a concentration-dependent manner (Figure 8A).
In the case of MCF-7 cells, the IC50 value for compound 4h
was 3.74 μM, while for HepG2 cells, the IC50 value of 4h was
5.99 μM. However, the toxicity of the compound was
evaluated on noncancerous cells (HEK293), and up to 100
μM, the compound did not affect the viability of noncancerous
cells (Figure 8B). These results advocate that compound 4h is
selectively inhibiting the growth of cancer cells (Table 2).
Apoptosis Studies. After getting remarkable results from
binding, enzyme assay, and cell viability studies on these
compounds, we have conducted an experiment to evaluate the
potential of apoptosis induction to understand the mechanism
of the selected compound before its therapeutic implications.
The MCF-7 and HepG2 cells were incubated with IC50 dose of
compound 4h. Annexin-V staining and PI staining were used
to study the apoptosis induction, and we found that compound
4h-treated cells underwent apoptosis as compared to untreated
controls (Figure 9). Compound 4h induces apoptosis in 11%
and 26% of MCF-7 cells, whereas in the case of HepG2, it
induces apoptosis in 28.1% and 20.8% of cells as compared to
untreated control cells at the studied concentration. These
results suggested that the selected compound caused the death
of cancerous cells through induction of apoptosis. Apoptosis
studies were consistent with earlier reports, which suggested
that the inhibitors/inhibition of MARK4 induces the cell death
in MCF-7 and other cancerous cells.29,33,49 All these
observations indicated the predominant therapeutic potential
of compound 4h.
Determination of Reactive Oxygen Species (ROS)
Level. Metabolic pathways and respiration lead to the
production of a variety of free radicals.50 The redox state of
cancerous cells plays an important role in cancer cells growth
and proliferation.51 To check out the redox potential of the
compound 4h, the level of ROS was measured after the
treatment of MCF-7 and HepG2 cells with this compound. It
was observed that after the treatment of the compound 4h, the
Table 2. MARK4 Inhibition and Human Cancer Cell








4a >20 37.32 38.53
4b >20 34.44 32.66
4c >20 32.54 33.22
4d >20 33.27 35.42
4e 18.45 23.32 21.54
4f >20 28.82 24.77
4g 16.22 22.54 25.32
4h 1.47 3.74 5.99
Figure 6. Compound 4h has specificity toward MARK4. (A) Kinase inhibition results with a panel of 30 kinases for compound 4h. (B) Pie chart
presentation for selectivity data. The selected panel of 30 kinases was incubated with 10 μM dose of each compound and analyzed for percent
activity values. The percent kinase activity was calculated and presented as a percentage of inhibition (%). In a total of 30 kinases, 23 kinases
showed <20% inhibition, 6 kinases showed 20−40% inhibition, and only MARK4 exhibited >80% inhibition.
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DCF fluorescence decreases, which suggests a decrease in the
level of ROS production (Figure 10). It was also reported
previously that MARK4 promoted the oxidative stress and
inhibition of MARK4 decreases the ROS level.30 Thus, our
results of ROS estimation are also in agreement with the earlier
reports that inhibition of MARK4 may lead to the decrease in
ROS generation and thus controls cancer growth and
proliferation.
■ DISCUSSION
In the quest for potent and selective MARK4 inhibitors, a
series (Scheme 1) of arylaldoxime/5-nitroimidazole hybrids
(4a−4h) were designed and synthesized following multistep
chemical reactions. All these compounds have a free N−OH
group as a backbone of the molecules coupled with varied
terminal aryl groups. In Scheme 1, the nitroimidazole ring was
grafted with various arylaldoximes for the determination of the
effect of the electron-deficient nitroaromatic fragment on the
overall activity of the target compounds. On the basis of
molecular docking, fluorescence binding studies, and enzy-
matic assays, a small hybrid chemotype 4h (IC50 = 1.47 μM)
was identified as the promising MARK4 inhibitor. The
compound 4h was found to be more potent probably due to
the additional interactions of the electron-withdrawing nitro-
imidazole ring with the Asp196, Lys85, and Val70 residues
besides the other core interactions as per molecular docking
studies. This compound showed the prominent inhibition of
MARK4 protein among the panel of 30 kinases belonging to
the serine/threonine family, which indicates the remarkable
selectivity toward MARK4 inhibition. The HSA binding
constant estimated as 3.6 × 103 M−1 for the compound 4h
indicates that such molecules may be easily transported and
delivered via blood to the target site for the desired
pharmacological effect.
Further, the compound 4h showed a considerable
antiproliferative potential against human cancer cell line
MCF-7 (IC50 = 3.74 μM) and HepG2 cell line (IC50 = 5.99
μM). The compound 4h was found to induce apoptosis in 11%
MCF-7 and 28.1% HepG2 cancerous cells, indicating that the
designed compounds may be used as the significant lead
candidates for the further development of MARK4 inhibitors
with appreciable apoptotic potential. The strong antioxidant
potential of the 4h compound in MCF 7 and HepG2 cells is
most probably due to the combined effect of the presence of a
free −NOH group, structural features of molecules, and their
MARK4 inhibition potential. In the present study, we consider
the combined antioxidant effect of oximes and MARK4 down-
regulation responsible for the antioxidant activity as both
oximes and MARK4 inhibition have been independently
reported for the reduction of ROS in the cancer cells.29,31,52
MARK4 overexpression has been reported for the induction of
oxidative stress in adipocytes, and inhibition of MARK4 helps
relieve oxidative stress.30 Interestingly, our results also
Figure 7. Compound 4h binding affinities with MARK4 and HSA. (A) Fluorescence emission spectra of MARK4 (10 μM) and HSA (25 μM) with
increasing concentrations of 4h, showing quenching of MARK4/HSA fluorescence with increasing concentration of 4h; excitation wavelength is
280 nm and emission range is 300−400 nm. (B) Modified Stern−Volmer plot conquered from the quenching of MARK4/HSA fluorescence with
increasing concentration of 4h, used to calculate the binding affinity (Ka).
Figure 8. Cell viability studies. (A) Effect of compound 4h on the
viability of MCF-7 and HepG2 vs log concentration of compound 4h.
(B) Graphical representation for cell viabilities of HEK293 cells. Each
of the selected cells was treated with increasing concentrations of
compound 4h for 48 h. Cell viabilities were presented as the
percentage of the number of viable cells to that of the control. Each
data point shown is the mean ± SD from n = 3. (For anticancer
activities, paclitaxel has been taken as the positive control.)
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suggested that inhibition of MARK4 by selected compounds
reduces the ROS levels. Thus, present results also support the
observations of previous studies in relation to the association
of ROS, MARK4 expression, and cancer progression.29,30,34 In
addition, all the compounds were observed to have appreciable
water solubility in the range of 10 ± 0.01 to 103 ± 2.1 mg/mL,
indicating their efficient bioavailability (Table S3).
Most kinase inhibitors exhibit off-target interactions that
occur through a pathway cross-talk or lack of selectivity,
causing unanticipated side effects.53−55 Our synthesized
compounds exerted selective MARK4 inhibitory potential
having a minimal effect over other 30 kinases of the serine/
threonine family, which indicates minor off-target interactions.
Further, ROS generation causes DNA damage and mutation
and facilitates tumor progression. It is therefore plausible that
compounds having an antioxidant potential could minimize the
genotoxic effects caused by ROS and reduce the incidence of
carcinogenesis.56,57 Compound 4h showed the appreciable
antioxidant potential apart from selective inhibition of MARK4
protein kinase. In addition, the efficient binding affinity with
HSA and fair aqueous solubility renders such compounds
remarkable therapeutic potential. Often, the kinase inhibitors/
drugs are difficult to synthesize, possess low yield, and involve
harsh chemical reactions, making them expensive.58 The ease
of synthesis, small-molecule nature, least off-target interactions,
and significant antioxidant potential associated with our
synthesized molecules adds them as a new class of compounds
as potent inhibitors of MARK4. In nutshell, the molecular
hybridization of the 5-nitroimidazole scaffold with the
substituted oxime core led to the identification and emergence
of novel potent MARK4 inhibitors, having appreciable
apoptotic activity, antiproliferative effect, bioavailability, and
significant antioxidant potential.
■ CONCLUSIONS
We have synthesized water-soluble novel arylaldoxime/5-
nitroimidazole small-molecule hybrids as potent MARK4
inhibitors and antiproliferative agents. The molecule 4h has
been identified as the predominant apoptotic and significant
antioxidant agent besides having a promising selective MARK4
inhibition profile. Compound 4h can be easily transported via
blood to the target site and holds the efficient binding toward
MARK4 as compared to the 30 screened CAMK enzymes. The
observed potency of the compound 4h indicates that the
presence of the trifluoromethyl group owns the remarkable
significance for the designing of potent MARK4 inhibitors.
The pharmacological effectiveness assessed signifies the
valuable importance of oxime derived small molecules in
medicinal chemistry for targeting the MARK4 enzyme with
concomitant cellular free radical scavenging property and
efficient bioavailability. The results divulged that the
pharmacophoric hybridization approach is an effective tool
for the design and development of promising MARK4
inhibitors. The synthesized arylaldoxime/5-nitroimidazole
hybrid chemotypes may act as lead molecules for the designing
of new drug candidates having an improved therapeutic profile
for the future clinical development in anticancer drug paradigm
in terms of MARK4 inhibition.
■ EXPERIMENTAL SECTION
Materials and Methods. All the required chemicals were
purchased from Merck and Aldrich Chemical Company
(USA). The reagents were of analytical grade and were used
Figure 9. Compound 4h treatment induces apoptosis in human cancer cell lines. The MCF-7 and HepG2 cells were treated with IC50
concentrations of compound 4h for 10 h and processed for apoptosis analysis using Annexin-V/PI apoptosis kit. (A) Histogram showing the anti-
FITC-Annexin-V- and PI-stained cells after the treatment of compound 4h. The name of the cell line is indicated on the right side of histogram. (B)
Bar graphs represent the percentage of apoptotic cells stained with Annexin-V for duplicate measurements ± SD. Statistical analysis was performed
using t-test for unpaired samples, and the p-value is calculated by comparing the treated cells with vehicle control (V.C.).
Figure 10. Compound 4h decreases the ROS production in human
cancer cell lines. (A) Bar graphs represent the relative intensity of
DCF fluorescence for triplicate measurements. Cells were treated with
IC50 dose of compound 4h for 5−6 h and processed for ROS
measurements using DCFDA staining by spectrofluorimetry. Stat-
istical analysis was performed using t-test for unpaired samples; the p-
value is calculated by comparing the treated cells with vehicle control
(V.C.).
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as supplied. Percolated aluminum sheets (Silica gel 60 F254,
Merck Germany) were employed for thin-layer chromatog-
raphy (TLC). The synthesized compounds were visualized on
TLC using ultraviolet (UV) light (λ = 254 nm). The melting
points of all the compounds were observed on a Veego
instrument with model specifications REC-22038 A2 and are
uncorrected. 1H NMR and 13C NMR were recorded on Bruker
Spectrospin DPX 300 MHz and Bruker Spectrospin DPX 75
MHz spectrometers, respectively, using DMSO-d6 as a solvent
and trimethylsilane (TMS) as the internal standard. Splitting
patterns are designated as follows: s, singlet; d, doublet; t,
triplet; m, multiplet; Ar, aromatic; imid, imidazole. The mass
spectra of all the compounds were recorded by ESI-MS (AB-
Sciex 2000, Applied Biosystem).
Synthesis of Compounds (2a−2h and 3a−3h). The
synthesis of intermediates (2a−2h) and carboximidoyl
chlorides (3a−3h) is given in the Supporting Information.
Synthesis Protocol Employed for the Preparation of
Arylaldoxime/5-Nitroimidazole Hybrids (4a−4h). 2-
Methyl-4(5)-nitroimidazole (0.9 mmol) was dissolved in
ACN (5 mL). Anhydrous K2CO3 (2.7 mmol) and phase-
transfer catalyst TBAB (0.03 mmol) were added to the mixture
followed by the dropwise addition of ACN solutions of
synthesized carboximidoyl chlorides (4a−4h, 0.9 mmol). The
reaction mixture was refluxed for 3−4 h and the progress of
reaction was monitored by employing thin-layer chromatog-
raphy (TLC) visualized under 254 nm UV irradiation. After
completion, the reaction mixture was cooled down to room
temperature and then partitioned between chloroform and
water. The aqueous layer was extracted three times with
chloroform. The combined organic phase was washed with
brine, dried over Na2SO4, filtered, and concentrated in vacuo
under reduced pressure. The product was recrystallized from
chloroform and absolute ethanol to afford the target
compounds (4a−4h).
N-[(2-Methyl-5-nitro-1H-imidazol-1-yl) (phenyl)-
methylidene]hydroxylamine (4a). Yield: 93%; white solid;
m.p.: 253 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.63 (s,
1H, N-OH), 8.56 (s, 1H, imid-H), 7.55−7.45(m, 5H, Ar-H),
2.18 (s, 3H, imid-CH3).
13C NMR (75 MHz, DMSO-d6):
147.07, 145.38, 143.28, 141.35, 130.22, 128.37, 123.93, 121.93,
13.53. ESI-MS (m/z): [M+ + 1] 106.22. Anal. calcd. for
C11H10N4O3: C, 53.66; H, 4.09; N, 22.75. Found: C, 53.46; H,
3.99, N 22.55.
N-[(4-Methoxyphenyl)(2-methyl-5-nitro-1H-imidazol-1-
yl)methylidene]hydroxylamine (4b). Yield: 93%; white solid;
m.p.: 257−258 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.35
(s, 1H, N-OH), 8.51 (s, 1H, imid-H), 7.41 (d, 2H, J = 9 Hz,
Ar-H), 7.04 (d, 2H, J = 9 Hz, Ar-H), 3.80 (s, 3H, −OCH3),
2.18 (s, 3H, imid-CH3).
13C NMR (75 MHz, DMSO-d6): δ
161.74, 147.14, 145.11, 141.86, 127.72, 123.43, 121.91, 115.10,
55.87, 13.30. ESI-MS (m/z): [M+ + 1] 277.2. Anal. calcd. for
C12H12N4O4: C, 52.17; H, 4.38; N, 20.28. Found: C, 52.13; H,
4.31; N, 20.45.
N-[(2-Methyl-5-nitro-1H-imidazol-1-yl)(4-methylphenyl)-
methylidene]hydroxylamine (4c). Yield: 92%; white solid;
m.p.: 250 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.48 (s,
1H, N-OH), 8.51 (s, 1H, imid-H), 7.36−7.27 (m, 4H, Ar-H),
2.35 (s, 3H, imid-CH3), 2.27 (s, 3H, −CH3). 13C NMR (75
MHz, DMSO-d6): 147.17, 145.28, 142.08, 141.25, 130.22,
128.37, 125.98, 121.93, 21.35, 13.30. ESI-MS (m/z): [M+ + 1]
261.10. Anal. calcd. for C12H12N4O3: C, 55.38; H, 4.65; N,
21.53. Found: C, 55.25; H, 4.60; N, 21.67.
N-[(4-Ethoxyphenyl)(2-methyl-5-nitro-1H-imidazol-1-yl)-
methylidene]hydroxylamine (4d). Yield: 88%; yellow solid;
m.p.: 261 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.35 (s,
1H, N-OH), 8.53 (s, 1H, imid-H), 7.39 (d, 2H, J = 7.8 Hz, Ar-
H), 7.02 (d, 2H, J = 7.8 Hz, Ar-H), 4.10−4.04 (q, 2H, −CH2),
2.18 (s, 3H, imid-CH3), 1.36−1.31 (t, 3H, J = 13.5 Hz,
−CH3). 13C NMR (75 MHz, DMSO-d6): 161.02, 147.13,
145.31, 141.86, 127.70, 123.26, 121.91, 115.50, 63.88, 14.94,
13.31. ESI-MS (m/z): [M+ + 1] 291.02. Anal. calcd. for
C13H14N4O4: C, 53.79; H, 4.86; N, 19.30. Found: C, 53.84; H,
4.80; N, 19.45.
N-[(4-Ethylphenyl)(2-methyl-5-nitro-1H-imidazol-1-yl)-
methylidene]hydroxylamine (4e). Yield: 85%; yellow solid;
m.p.: 258−259 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.34
(s, 1H, N-OH), 8.52 (s, 1H, imid-H), 7.38 (d, 2H, J = 8.4 Hz,
Ar-H), 7.03 (d, 2H, J = 8.4 Hz, Ar-H), 2.17 (s, 3H, imid-CH3),
1.76−1.70 (q, 2H, −CH2), 0.99−0.94 (t, 3H, J = 7.5 Hz,
−CH3). 13C NMR (75 MHz, DMSO-d6): 161.19, 147.14,
145.30, 141.86, 127.70, 123.26, 121.91, 115.50, 63.88, 14.94,
13.31. ESI-MS (m/z): [M+ + 1] 275.01. Anal. calcd. for
C13H14N4O3: C, 56.93; H, 5.14; N, 20.43. Found: C, 56.87; H,
5.23; N, 20.38.
N-[(4-Chlorophenyl)(2-methyl-5-nitro-1H-imidazol-1-yl)-
methylidene]hydroxylamine (4f). Yield: 90%; white solid;
m.p.: 255 °C. 1H NMR (300 MHz, DMSO-d6): δ 12.11 (s,
1H, N-OH), 8.50 (s, 1H, imid-H), 7.41(d, 2H, J = 8.7 Hz, Ar-
H), 7.04 (d, 2H, J = 8.7 Hz, Ar-H), 2.18 (s, 3H, imid-CH3).
13C NMR (75 MHz, DMSO-d6): 162.74, 147.14, 145.11,
141.86, 127.72, 123.43, 121.91, 115.10, 55.87, 13.11. ESI-MS
(m/z): [M+ + 1] 281.44. Anal. calcd. for C11H9ClN4O3: C,
46.87; H, 3.23; N, 19.96. Found: C, 47.07; H, 3.21; N, 19.85.
N-[(2-Methyl-5-nitro-1H-imidazol-1-yl)(4-nitrophenyl)-
methylidene]hydroxylamine (4g). Yield: 87%; yellow solid;
m.p.: 260 °C. 1H NMR (300 MHz, DMSO-d6): δ 13.25 (s,
1H, N-OH), 8.60 (s, 1H, imid-H), 8.31 (d, 2H, J = 8.7 Hz, Ar-
H), 7.76 (d, 2H, J = 8.7 Hz, Ar-H), 2.20 (s, 3H, imid-CH3).
13C NMR (75 MHz, DMSO-d6): 147.34, 145.48, 140.97,
137.09, 131.05, 127.36, 110.76, 110.28, 13.33. ESI-MS (m/z):
[M+ + 1] 292.07. Anal. calcd. for C11H9N5O5: C, 45.37; H,
3.11; N, 10.05. Found: C 45.42; H, 3.06; N, 10.16.
N - { ( 2 -M e t h y l - 5 - n i t r o - 1 H - im i d a z o l - 1 - y l ) [ 2 -
(trifluoromethyl)phenyl]methylidene}hydroxyl Amine (4h).
Yield: 94%; white solid; m.p.: 270 °C. 1H NMR (300 MHz,
DMSO-d6): δ 13.04 (s, 1H, N-OH), 8.39 (s, 1H, imid-H),
7.95−7.92 (m, 1H, Ar-H), 7.83−7.76 (m, 2H, Ar-H), 7.62 (d,
1H, J = 7.8 Hz, Ar-H), 2.18 (s, 3H, imid-CH3).
13C NMR (75
MHz, DMSO-d6): 145.67, 139.07, 133.58, 111.43, 131.76,
129.73, 127.91, 127.49, 125.79, 122.16, 121.90, 14.43. ESI-MS
(m/z): [M+ + 1] 315.21. Anal. calcd. for C12H9F3N4O3: C,
45.87; H, 2.89; N, 17.83. Found: C, 45.92; H, 2.72; N, 17.97.
X-ray Crystal Structure Determination. Three-dimen-
sional X-ray data were collected on a Bruker Kappa Apex CCD
diffractometer at low temperature for compounds 4c and 4e by
the ϕ−ω scan method. Reflections were measured from a
hemisphere of data collected from frames, each of them
covering 0.3° in ω. A total of 31,157 reflections measured for
4c and 130,390 for 4e were corrected for Lorentz and
polarization effects and for absorption by multiscan methods
based on symmetry-equivalent and repeated reflections. Of the
total, 2360 independent reflections for 4c and 4869 for 4e
exceeded the significance level (|F|/σ|F|) > 4.0 > 4.0. After data
collection, in each case, the multiscan absorption correction
(SADABS)59 was applied, and the structure was solved by
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direct methods and refined by full-matrix least squares on F2
data using SHELX suite of programs.60 Hydrogen atoms were
located in a difference Fourier map and left to refine freely,
except for C(11) and C(12) in 4c and C(11), C(12), C(13),
C(24), C(16A), C(16B), C(17A), C(17B), C(25A), C(25B),
C(26A), and C(26B) in 4e, which were included in the
calculation position and refined in the riding mode. Refine-
ments were done with allowance for thermal anisotropy of all
nonhydrogen atoms. A final difference Fourier map showed no
residual density outside: 0.347 and −0.299 e Å−3 for 4c; 0.364
and −0.398 e Å−3 for 4e. w = 1/[σ2(Fo2) + (0.044300P)2 +
0.660000P] for 4c and 1/[σ2(Fo
2) + (0.037200P)2 +
1.466400P] for 4e, where P = (|Fo|
2 + 2|Fc|
2)/3, were used
in the latter stages of refinement. An important disorder on
one molecule of the two present in the asymmetric unit
appears in the crystal of 4e. This disorder has been refined and
two atomic sites have been observed and refined with the
anisotropic atomic displacement parameters for the ethyl-
phenyl group. More specifically, this disorder was refined using
142 restraints (ISOR, SADI, SIMU, and DELU restraints were
used). The site occupancy factor was 0.51705 for C(16A),
C(17A), C(18A), C(24A), and C(25A). Further details of the
crystal structure determination are given in Table 1. CCDC
1965977 and 1965978 numbers contain the supplementary
crystallographic data for the structures reported in this paper.
These data can be obtained free of charge via https://www.
ccdc.cam.ac.uk/structures/ or from the Cambridge Crystallo-
graphic Data Centre, 12 Union Road, Cambridge CB2 1EZ,
U.K.; fax: (+44) 1223 336 033; e-mail: deposit@ccdc.cam.a-
c.uk.
Molecular Docking. Molecular docking of the synthesized
arylaldoxime hybrids was carried out using Autodock Vina and
AutoDock 4 package.45,61 The atomic coordinates of MARK4
were taken from RCSB Protein Data Bank (PDB ID 5ES1).36
The 2D and 3D structures of all the synthesized hybrid
molecules were drawn in ChemBio3D Ultra 12.0. For viewing
of the binding affinity, bound conformations, and possible
protein−ligand interactions, the coordinate files of MARK4
and respective synthesized arylaldoxime hybrids were subjected
to molecular docking. For visualization and structure analysis
of the docked complexes of MARK4 and also to generate 2D
docking for the analysis of hydrogen bonds and hydrophobic
interactions, PyMOL viewer (Schrödinger, LLC) and
“Receptor-Ligand Interactions” modules of BIOVIA/Discovery
Studio 2017R2 were used.62
Enzyme Inhibition Assay. To evaluate the enzymatic
activity of MARK4, ATPase assay was performed in the
presence of synthesized arylaldoxime hybrids, as described
earlier.29,33 In brief, we have measured 32Pi liberated from
MARK4 arbitrated hydrolysis of [γ-32P] ATP. First, MARK4
was incubated along with ice-cold ATP (1 mM) having
radioactive-labeled [γ-32P] ATP (specific activity, 222 TBq
mmol−1) for 2 h at 37 °C and, subsequently, TLC was
performed. Initially, the experiments were conducted for
screening of active compounds after the initial screening
activity of MARK4 was monitored with ascending concen-
trations of the selected compound. The inference of MARK4
inhibition in terms of percentage hydrolysis of ATP was
established using ImageJ software (https://imagej.nih.gov/ij/
index.html).
Single-Dose Kinase Inhibition Profiling. In vitro
biochemical profiling of compound 4h was evaluated with
the 26 members of CAMK family (CAMK-1 and CAMK-2) of
kinases using kinase screening kit by following the
manufacturer’s protocols (Promega, Madison, USA), as
described previously.32,63 Briefly, 10 μM of compound was
added to the corresponding well of 384-well assay plate.
Serially, 2 μL of kinase solution was added to each well of the
plate. The reaction mixture was mixed gently using a plate
shaker for 2 min. The plate was centrifuged and incubated at
room temperature (25 °C) for 10 min. Following the
incubation period, 2 μL of working stocks of ATP/substrate
was added carefully to the respective well. Shake the assay
plate, centrifuge, and incubate at room temperature (25 °C)
for 60 min. Consequently, 5 μL of ADP-Glo reagent was added
to all reaction wells of the assay plate. The plate was shaken for
2 min and incubated further at room temperature for 40 min.
As a final point, 10 μL of Kinase Detection Reagent was added
to each reaction well and the plate was incubated at room
temperature for 30 min. After the completion of reaction,
luminescence was measured using an integration time of 0.5 s
per well. Using net luminescence of the no-compound control
(negative control) reactions to represent 100% kinase activity,
the percent kinase activity was calculated in the compound-
containing reactions and plotted in terms of percent kinase
activity inhibition. Additionally, as our laboratory is working on
different human kinases named calcium−calmodulin-depend-
ent protein kinase IV (CAMKIV), Fas-activated serine/
threonine kinase (FASTK), PDK3, and integrin-linked kinase
(ILK), so we have also studied the selectivity/inhibition
potential of compound 4h by malachite green assay, as per our
previously published protocol.64
Fluorescence Measurements. Binding affinities of the
synthesized arylaldoxime hybrid 4h with MARK4 were
determined using the fluorescence intensity change in the
emission spectrum of MARK4, as per our published protocol.64
The titration of protein was done in triplicates and, for analysis,
their average was taken. A significant decrease in the
fluorescence intensity of protein with increasing concentration
of the selected arylaldoxime hybrid was used to calculate the
binding constant (Ka) and the number of binding sites (n)
present on the protein molecule by using the modified Stern−
Volmer equation.65
− = + [ ]F F F K n Llog( )/ log logo a (1)
where Fo is the fluorescence intensity of native protein, F is the
fluorescence intensity of protein in the presence of ligand, Ka is
the binding constant, n is the number of binding sites, and L is
the concentration of ligand. The binding constant (Ka) and
number of binding sites (n) were obtained from the intercept
and slope, respectively.
Cell Viability Assay. To estimate the cancerous cell
growth inhibitory potential of synthesized compounds, MTT
assay was carried out.29,64 Briefly, cells were plated at a density
of 8000−9000 cells/well in a 96-well cell culture plate. After 10
h, cells were incubated with different concentrations (0.1−80
μM) of compound 4h for 48 h at 37 °C in a humidified CO2
incubator. After 48 h, the mixture of media and compound was
removed, and 20 μL of MTT solution (from 5 mg/mL stock
solution in PBS, pH 7.4) and 100 μL of DMEM were added to
each well of the culture plate. The plates were incubated for 4−
5 h at 37 °C in the CO2 incubator. The supernatant of each
well was removed and the formazan crystals were dissolved by
adding 100 μL of DMSO to each well. The absorbance (A) of
the reaction product was measured at 570/590 nm on a
multiplate ELISA reader (Bio-Rad). The percentage cell
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viability was calculated and it was used to estimate the IC50
(50% inhibitory concentration) value for compound 4h. For
cell proliferation and anticancer activities, paclitaxel was used
as a positive control.
Apoptosis Assay. Induction of apoptosis was analyzed
using Annexin-V staining, as described previously.3,64 Briefly,
2.5 × 105 cells/well of a six-well culture plate were plated.
Once the cells were grown to 80% confluency, they were
incubated with IC50 concentration of 4h for 10 h at 37 °C. The
control cells were treated with media only. After 10 h
treatment, cells were harvested by trypsinization and collected
by centrifuging them at 2000−3000 rpm for 4 min. Cells were
washed three times with PBS and incubated in Annexin
binding buffer with FITC-Annexin-V and PI using FITC-
Annexin-V kit following the manufacturer’s guidelines (BD
Biosciences, USA). Around 10,000 events were collected for
each sample using flow cytometry (BD LSR II Flow Cytometry
Analyzer) and analyzed by FlowJo.
Estimation of ROS Production. 2′,7′-Dichlorodihydro-
fluorescein diacetate (DCFH-DA) staining was used for
measuring the redox state of cells, as described previously.29,64
Briefly, the MCF-7 and HepG2 cells were plated at a density of
2.5 × 105 cells/well of the six-well plate. On the next day, cells
were respectively treated with IC50 dose of compound 4h in a
10-well culture plate for 5−6 h (H2O2 is used as a positive
control). Cells were washed with 500−1000 μL of prewarmed
(at 37 °C) Krebs Ringer buffer (20 mM HEPES, 2 mM
MgSO4, 10 mM dextrose, 127 mM NaCl, 1 mM CaCl2, and 5.5
mM KCl). Subsequently, cells were incubated with DCFDA
(10 μM) for 30 min in the dark at 37 °C in a humidified CO2
incubator. After 30 min incubation, the cells were harvested by
trypsinization and collected by centrifugation. ROS levels were
assessed by measuring the fluorescence at a Jasco spectro-
fluorimeter (FP-6200) using a 5 mm quartz cuvette. The
excitation and emission filters were set at 485/500−550 nm,
respectively.
Solubility Assay. Twenty milligrams of each the target
compound was taken in a polypropylene microcentrifuge tube
(2 mL strength) and 100 μL of citrate-buffered solution (pH
3.3) was added and then incubated on an Eppendorf
Thermomixer (1000 rpm) at 25 °C. The compounds were
centrifuged at 20,800g for the time period of 2 min after
incubation and then subjected to filtration through a 0.22 μm
polyvinylidene difluoride (PVDF) membrane. Aliquots of the
obtained filtrates were diluted by solvents DMSO/acetonitrile
(ACN)/trifluoroacetic acid in the ratio of 80:20:0.1 and then
kept at 4 °C. An Agilent 1100 HPLC equipped with a Waters
Symmetry IS C18 column, (3.5 μm, 2.1 × 20 mm)
accompanied with a wavelength detection of 254 nm was
employed for further analysis. Water (0.1% trifluoroacetic acid)
and ACN (0.1% trifluoroacetic acid) systems were used as
mobile phases during analysis. The column was eluted with
10% ACN (0.1% trifluoroacetic acid) for 0.5 min at first, then
with 10% to 55% ACN (0.1% trifluoroacetic acid) over 9.5
min, and finally at the gradient of 70% ACN (0.1%
trifluoroacetic acid) for 1 min at the flow rate of 1 mL/min.
Peaks obtained were calibrated with the known standards and
then the solubility was assessed.
Statistical Analysis. Data were expressed as mean ±
standard error from three independent experiments. The
statistical analysis of each data was performed using the two-
tailed Student t-test for unpaired samples and values of p <
0.05 were considered as significant.
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